Topline Phase News Today

Ocular Therapeutix, Inc. announced positive topline results from the Phase 1 HELIOS study evaluating AXPAXLI versus a sham control in patients with moderately severe to severe non-proliferative...

18.04.2024 - 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to ... Seite 1

11.03.2024 - Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA in Glaucoma Expected in Q2 2024 Cash ...

Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial ...

Kiora Pharmaceuticals today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the companys first-i...

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersens...

08.05.2023 - - Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 - - Full Six-Month Safety Data from Both ...

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...